TuHURA Biosciences, Inc. HURA
1.62 USD -0.10 (-5.81%)
Nov 5, 2026, 1:36 PM EST
1.56 Day range 1.80
0.44 52-week range 3.15
- YTD
- +114.00%
- 1 year
- -35.20%
- Market cap
- 102.92M
- EPS (ttm)
- -0.54
- Forward P/E
- -14.31
- YTD return
- +114.00%
- 1-year return
- -35.20%
- Volume
- 401.65K
- Avg volume
- 293.70K
- Open
- 1.75
- Previous close
- 1.72
- Day's range
- 1.56 – 1.80
- 52-week range
- 0.44 – 3.15
- Price target
- 15.00 (+825.9%)
- Earnings date
- Feb 12, 2025
2Y -3.35 (-67.27%)
Key statistics
- Price / sales
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- 50-day average
- 5.22
- 200-day average
- 6.16
Analyst view
Price target (mean) 15.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 12, 2025
Expected Feb 12, 2025. Consensus EPS estimate -0.09.
Financials — quick view
HURA Revenue — quarterly 0
HURA Net income — quarterly -9.22M
HURA EPS — quarterly -0.14
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 12, 2025 | Dec 1, 2024 | 0.00 | — | — | — |
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -1.37 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | Rodman & Renshaw | init | — | Buy |
News
TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition 
HC Wainwright & Co. Reiterates Buy on TuHURA Biosciences, Maintains $10 Price Target 
TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study - TuHURA Reports Initial Data Showing Partial Responses In First Three Metastatic Merkel Cell Carcinoma Patients Treated With Ifx-2.0 Plus Keytruda
TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma 
12 Health Care Stocks Moving In Tuesday's After-Market Session 
TuHURA Biosciences Secures US Patent For TBS-2025, Entitled ‘Anti-VISTA Antibodies And Uses Thereof’ 
TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025 
TuHURA Biosciences Receives U.S. Patent For Administration Of DOR Antagonists 
TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
Your note
Sign in to keep a note on HURA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BIANCO JAMES A | Chief Executive Officer | Stock Award(Grant) | Oct 17, 2024 | 2,323,310 |
| HOFFMAN ROBERT E | Chief Executive Officer | Stock Award(Grant) | May 31, 2023 | 68,902 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.06% | 25,394 | 105.39K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.02% | 7,297 | 30.28K | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 0.01% | 4,558 | 18.91K | Sep 29, 2024 |
| UBS Group AG | 0.01% | 5,930 | 24.61K | Sep 29, 2024 |
| Clear Creek Financial Management, LLC | 0.00% | 1,571 | 6.52K | Sep 29, 2024 |
| Baader Bank Aktiengesellschaft | 0.00% | 864 | 3.58K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.02% | 8,960 | 37.18K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.01% | 2,489 | 10.33K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.00% | 712 | 2.95K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.00% | 1,546 | 6.42K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.00% | 870 | 3.61K | Oct 30, 2024 |